2023 cell and gene therapy industry survey

What’s ahead for the cell and gene therapy (CGT) market? Deloitte’s survey of CGT innovators, health care providers, and contract development and manufacturing organizations (CDMOs) reveals shared optimism for the gene therapy market while identifying areas for caution. Uncover insights to guide decision-making and strategic planning in the future of personalized medicine.

Stakeholders express positive outlook for cell and gene therapy market

Deloitte’s 2023 cell and gene therapy industry survey aimed to address the scarcity of CGT-specific information regarding past and future challenges across the value chain. The survey highlighted the key challenges and opportunities that organizations, their partners, and the broader cell and...